KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Payables (2016 - 2025)

Eli Lilly's Payables history spans 17 years, with the latest figure at $5.4 billion for Q4 2025.

  • For Q4 2025, Payables rose 17.57% year-over-year to $5.4 billion; the TTM value through Dec 2025 reached $5.4 billion, up 17.57%, while the annual FY2025 figure was $5.4 billion, 17.57% up from the prior year.
  • Payables reached $5.4 billion in Q4 2025 per LLY's latest filing, up from $4.3 billion in the prior quarter.
  • In the past five years, Payables ranged from a high of $5.4 billion in Q2 2025 to a low of $1.4 billion in Q1 2022.
  • Average Payables over 5 years is $3.0 billion, with a median of $2.7 billion recorded in 2021.
  • Peak YoY movement for Payables: skyrocketed 89.91% in 2021, then dropped 12.58% in 2022.
  • A 5-year view of Payables shows it stood at $2.6 billion in 2021, then increased by 15.32% to $2.9 billion in 2022, then grew by 27.82% to $3.8 billion in 2023, then rose by 21.43% to $4.6 billion in 2024, then rose by 17.57% to $5.4 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Payables are $5.4 billion (Q4 2025), $4.3 billion (Q3 2025), and $5.4 billion (Q2 2025).